Close

Jefferies Raises Price Target on Exact Sciences (EXAS) as HEDIS Includes Cologuard in Quality Measures

Go back to Jefferies Raises Price Target on Exact Sciences (EXAS) as HEDIS Includes Cologuard in Quality Measures

Exact Sciences (EXAS) Confirms Inclusion of Cologuard in HEDIS Quality Measures

October 3, 2016 12:36 PM EDT

Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS.

... More

Exact Sciences (EXAS) Gains as NCQA Updates Colorectal Cancer Screening Measure

October 3, 2016 12:09 PM EDT

Exact Sciences (NASDAQ: EXAS) gains as NCQA updates colorectal cancer screening measure.

From NCQA:

The National Committee for Quality Assurance (NCQA) has updated the HEDIS®Colorectal Cancer Screening measure in order to respond to recently revised scientific guidelines by the US Preventive... More